Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives

Molecular Pharmacology

Volumn 53, Issue 6, 1998, Pages 1097-1103

  Baba, Masanori ^a   Okamoto, Mika ^a   Kawamura, Masaki ^a   Makino, Masahiko ^a   Higashida, Tomoe ^b   Takashi, Tohru ^b   Kimura, Youichi ^b   Ikeuchi, Tohru ^b   Tetsuka, Toshifumi ^c   Okamoto, Takashi ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

'K 38'; 1,4 DIHYDRO 8 DIMETHYLAMINOMETHYL 6 FLUORO 7 [4 (2 METHOXYPHENYL) 1 PIPERADINYL] 1 METHYL 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 (3,4 DEHYDRO 4 PHENYL 1 PIPERIDINYL) 1,4 DIHYDRO 6 FLUORO 1 METHYL 8 TRIFLUOROMETHYL 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; 8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; GLYCYCLAMIDE; K 37; K 42; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DERIVATIZATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; TARGET CELL; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; CELL LINE; CYTOKINES; GENE PRODUCTS, TAT; HIV-1; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; QUINOLINES; TRANS-ACTIVATION (GENETICS); VIRUS REPLICATION;

EID: 0031866266     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Baba M (1997) Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Res 33:141-152.
2. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Nakashima H, Mori S, Shigeta S, Walker RT, and Miyasaka T (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 88:2356-2360.
3. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, and Okamoto T (1997) Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother 41:1250-1255.
4. Boschelli DH, Kramer JB, Connor DT, Lesch MK, Schrier DJ, Ferin MA, and Wright CD (1994) 3-Alkokybenzo[b]thiophene-2-carboxamides as inhibitors of neutrophil-endothelial cell adhesion. J Med Chem 37:717-718.
5. + cell model of chronic infection. J Virol 65:4645-4653.
6. Butera ST, Roberts BD, Critchfield JW, Fang G, McQuade T, Gracheck ST, and Folks TM (1995) Compounds that target novel cellular components involved in HIV-1 transcription. Mol Med 1:758-767.
7. Critchfield JW, Coligan JE, Folks TM, and Butera ST (1997) Casein kinase II is a selective target of HTV-1 transcriptional inhibitors. Proc Natl Acad Sci USA 94:6110-6115.
8. Critchfield JW, Folks TM, and Butera ST (1996) Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res Hum Retrovir 12:39-46.
9. Cullen BR (1991) Regulation of human immunodeficiency virus replication. Annu Rev Microbiol 45:219-250.
10. Epstein LG and Gendelman HE (1993) Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Annu Neurol 33:429-436.
11. Fauci AS (1993) Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science (Washington DC) 262:1011-1018.
12. Gendelman SE, Phelps W, Feigenbaum W, Ostrove JM, Adachi A, Howley PM, Khoury G, Ginsberg HS, and Martin MA (1986) Transactivation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 83:9759-9763.
13. Griffin GE, Leung K, Folks TM, Kunkel S, and Nabel G (1989) Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature (Lond) 339:70-73.
14. Janosch P, Schellerer M, Seitz T, Reim P, Eulitz M, Brielmeier M, Kolch W, Sedivy JM and Mischak H (1996) Characterization of IκB kinases. IκB-α is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate. J Biol Chem 271:19680-19688.
15. Jones KA and Peterlin BM (1994) Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 63:717-747.
16. Kikukawa R, Koyanagi Y, Harada S, Kobayashi N, Hatanaka M, and Yamamoto N (1986) Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic cell line Molt-4. J Virol 57:1159-1162.
17. Kimura T and Katsube T, inventors. Ube Industries, Ube, Japan, assignee (1993) Aminoquinoline derivatives as anti-HIV agents. European patent #572259 (December).
18. Luznik L, Kraus S, Gutatelli J, Richman D, and Wong-Staal F (1995) Tat-independent replication of human immunodeficiency virus. J Clin Invest 95:328-332.
19. Merrill JE and Chen IS (1991) HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J 5:2391-2397.
20. Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, and Akagi T (1982) Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr 28:219-228.
21. Morse HC III, Chattopadhyay SK, Makino M, Frederickson TN, Hugin AW, and Hartley JW (1992) Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6:607-620.
22. Nabel G and Baltimore D (1987) An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (Lond) 326:711-713.
23. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for detection of anti-HIV compounds. J Virol Methods 20:309-321.
24. Roederer M, Ela SW, Staal FJ, Herzenberg LA, and Herzenberg LA (1992) N-acetylcysteine: a new approach to anti-HIV therapy. AIDS Res Hum Retrovir 8:209-217.
25. Roulston A, Lin R, Beauparlant P, Wainberg MA, and Hiscott J (1995) Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-κB/Rel transcription factors. Microbiol Rev 59:481-505.
26. Schreck R, Rieber P, and Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 10:2247-2258.
27. Staal FJT, Roederer M, Helzenberg LA, and Helzenberg LA (1990) Intracellular thiols regulate activation of nuclear factor κB and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 87:9943-9947.
28. Thanos D and Maniatis T (1995) NF-κB: a lesson in family values. Cell 80:529-532.
29. Veschambre P, Simard P, and Jalinot P (1995) Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. J Mol Biol 250:169-180.
30. Witvrouw M, Pauwels R, Vandamme A, Schols D, Reymen D, Yamamoto N, Desmyter J, and De Clercq E (1992) Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob Agents Chemother 36:2628-2633.
31. Zhou Q and Sharp PA (1995) Novel mechanism and factor for regulation by HIV-1 Tat. EMBO J 14:321-328.